INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by INVO Bioscience, Inc. on October 11, 2017, covering events that occurred on October 10, 2017. The filing details significant changes to the Company's Board of Directors and governance structure.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The text notes that the Company is "still underfunded," which influenced compensation decisions for new directors.
Material Changes
- Board Expansion: The Board of Directors was expanded from three (3) members to five (5) members via an amendment to the Bylaws.
- New Director Appointments: Michael J. Campbell and Stephen M. Shum were unanimously elected to the Board to fill the new vacancies.
- Compensation Structure: Due to the Company's underfunded status, independent directors will be compensated solely with restricted stock rather than cash. Each independent director is to receive 200,000 restricted shares of Common Stock for the 2017-2018 period, totaling 600,000 shares.
Outlook, Risks, and Management Commentary
Management expressed a warm welcome to the new directors, highlighting their extensive experience in medical device sales, marketing, and finance. Mr. Campbell brings over 10 years of experience at Cooper Surgical, while Mr. Shum has served as CFO for Eastside Distilling and held executive roles at XZERES Corp. The filing states there are no arrangements or understandings between the new directors and existing directors regarding their election. No specific risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the issuance of 600,000 restricted shares of Common Stock to independent directors and the impact on share dilution.
- Confirm the updated composition of the Board of Directors and the absence of board committees.
- Review the Company's capital position given the disclosure that it is "still underfunded."
- Check for any subsequent filings regarding the vesting schedule or restrictions on the newly issued shares.